Identification of a Novel Heart–Liver Axis: Matrix Metalloproteinase‐2 Negatively Regulates Cardiac Secreted Phospholipase A2 to Modulate Lipid Metabolism and Inflammation in the Liver
Autor: | Tae Jin Yun, János G. Filep, Cheolho Cheong, Vesna Brglez, Samuel Hernandez-Anzaldo, Zamaneh Kassiri, Dickson Leung, Richard Lehner, Evan Berry, Carlos Fernandez-Patron, Jun Seong Lee, Gérard Lambeau |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2015 |
Předmět: |
Indoles
Time Factors Transcription Genetic 030204 cardiovascular system & hematology Acetates Hepatitis Cholesterol Dietary 0302 clinical medicine Medicine Myocytes Cardiac Chemokine CCL7 Enzyme Inhibitors Cells Cultured Original Research Regulation of gene expression Mice Knockout 0303 health sciences biology Keto Acids 3. Good health medicine.anatomical_structure Phenotype Matrix Metalloproteinase 2 Signal transduction medicine.symptom Cardiology and Cardiovascular Medicine Signal Transduction medicine.medical_specialty matrix metalloproteinase Inflammation heart liver Antibodies 03 medical and health sciences Phospholipase A2 Internal medicine Animals Secretion Genetic Predisposition to Disease Liver X receptor Phospholipases A2 Secretory Triglycerides 030304 developmental biology business.industry Monocyte Lipid metabolism Lipid Metabolism Mice Inbred C57BL Endocrinology Gene Expression Regulation inflammation biology.protein phospholipase A2 business metabolism |
Zdroj: | Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease |
ISSN: | 2047-9980 |
Popis: | Background Endocrine functions of the heart have been well established. We investigated the hypothesis that cardiac secretion of a unique phospholipase A 2 recently identified by our laboratory (cardiac secreted phospholipase A 2 [ sPLA 2 ]) establishes a heart–liver endocrine axis that is negatively regulated by matrix metalloproteinase‐2 (MMP‐2). Methods and Results In Mmp2 −/− mice, cardiac (but not hepatic) sPLA 2 was elevated, leading to hepatic inflammation, immune cell infiltration, dysregulation of the sterol regulatory element binding protein‐2 and liver X receptor‐α pathways, abnormal transcriptional responses to dietary cholesterol, and elevated triglycerides in very low‐density lipoprotein and in the liver. Expression of monocyte chemoattractant protein‐3, a known MMP‐2 substrate, was elevated at both mRNA and protein levels in the heart. Functional studies including in vivo antibody neutralization identified cardiac monocyte chemoattractant protein 3 as a possible agonist of cardiac sPLA 2 secretion. Conversely, systemic sPLA 2 inhibition almost fully normalized the cardiohepatic phenotype without affecting monocyte chemoattractant protein‐3. Finally, wild‐type mice that received h igh‐performance liquid chromatography –isolated cardiac sPLA 2 from Mmp2 −/− donors developed a cardiohepatic gene expression profile similar to that of Mmp2 −/− mice. Conclusions These findings identified the novel MMP‐2/cardiac sPLA 2 pathway that endows the heart with important endocrine functions, including regulation of inflammation and lipid metabolism in the liver. Our findings could also help explain how MMP 2 deficiency leads to cardiac problems, inflammation, and metabolic dysregulation in patients. |
Databáze: | OpenAIRE |
Externí odkaz: |